Stanislav Glezer Joins Outcome Capital as Managing Director

Outcome Capital LLC has appointed Stanislav Glezer, M.D. as managing director.

Glezer most recently was with Inogen Inc, a medical technology company offering respiratory products for homecare setting use, serving as executive vice president of R&D and chief medical officer. Under his leadership, the company secured an MDR certification; developed and obtained U.S. Food and Drug Administration 510(k) clearance for several devices; acquired a French medical technology company; and completed several clinical trials and real world evidence projects, resulting in peer reviewed publications and posters at international conferences. Before his Inogen tenure, Glezer worked for Becton, Dickinson and Company as worldwide vice president of Medical Affairs for Diabetes Care and had business development responsibilities. Before joining Becton Dickinson, was the chief medical officer at Adocia S.A. and vice president of Global Medical Affairs at Novo Nordisk Inc.

Earlier in his career, Glezer held a number of medical affairs and medical strategy roles of progressively increasing seniority for Sanofi S.A.
 
“On behalf of the Outcome Capital team, I congratulate Stan on this appointment as I am confident that he will be a tremendous asset to our firm and to our clients,” Outcome Managing Partner Oded Ben-Joseph, Ph.D., said. “I believe Stan’s 30 years of experience in clinical research and medical affairs roles with strong experience in R&D, regulatory, commercial, market access and other areas across a variety of medical technology and biopharmaceutical firms will assist in driving Outcome Capital’s growth strategy and elevate our overall capabilities for the benefit of our clients.”
 
Glezer earned a doctor of Medicine with Honors degree from Moscow State University of Medicine and Dentistry and an MBA from California Coast University. He has completed training in health economics and clinical research at McGill University and is currently participating in the CEO Program at Columbia University Business School.

“I am honored by the opportunity to join Outcome Capital as a managing director,” Glezer stated. “This role is well aligned with my personal mission of improving patients’ outcomes through innovation. I look forward to partnering with medical technology and biopharmaceutical companies to help advance their products and projects to commercialization and beyond by providing advisory services, identifying potential sources of funding and supporting preparation and execution of the transactions with the right partners.”
 
Outcome Capital is a highly specialized life sciences and healthcare advisory and investment banking firm, providing companies with a value-added, market-aligned approach to mergers and acquisitions, partnering, and corporate finance. The firm leverages its strategy-led execution approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their relationships and varied scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, Ph.D./M.D.-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside.